TP53 and lung adenocarcinoma: Instead, in lung adenocarcinoma, previous studies reported TP53 mutated more frequently in high TMB tumors (define: > 4.85 mutations/Mb) [42], and had potential predictive value for response to PD-1 blockade immunotherapy.